Glossary, CRG, NHLBI, NIH

Recombinant DNA and Gene Transfer Approval
FDA
Food and Drug Administration (FDA)
is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation. Food and Drug Administration Homepage
Drug or Device Studies Approval
Stem Cell Study Approval

National Institutes of Health (NIH)
the United State's medical research agency, a federal government agency composed of diverse Institutes and Centers that conduct and support biomedical and behavioral research. NIH Homepage.

Guidelines for Recombinant DNA state that no research participant will be enrolled in gene transfer studies (Phase I, II, or III) until the Recombinant DNA Advisory Committee ( RAC

Recombinant DNA Advisory Committee (RAC)
experts whose responsibility it is to review human gene transfer research, receiving NIH funding for recombinant DNA research. Protocols are discussed at quarterly public meetings. RAC Homepage

) review has been completed, Institutional Review Board and Institutional Biosafety Committee ( IBC

Institutional Biosafety Committee (IBC)
oversight group convened by a research institution under NIH Guidelines for Research Involving Recombinant DNA Molecules to review recombinant DNA research and ensure its legal use. IBCs may also review other biohazardous research, including biodefense select agents.

) approvals have been obtained, and an Investigational New Drug request has been authorized. NIH Guidelines apply to investigators conducting gene transfer research that are supported by NIH or performed at an Institution that receives NIH support for any type of recombinant DNA research.

FDA approvals are required for studies that use:

An unapproved or unlicensed drug or device.
An FDA licensed drug or device used in a manner for which it has not been licensed (“off label use”).
A drug or device formulated or developed by an organization that does not hold an FDA license for its manufacture.
An unapproved or unlicensed gene delivery vector containing a gene or DNA product.

You may need to obtain an IND

Investigational New Drug (IND)
an application, filed by a drug sponsor with FDA (Form FDA 1571) to conduct clinical trials. It includes detailed descriptions of all trial phases, protocols, IRB members, and investigators

or IDE

Investigational Device Exemption (IDE)
similar to an IND, this allows an unapproved medical device to be used for investigational purposes.

approval for your study drug or device. A physician who both initiates and conducts an investigation in which an investigational drug is administered or dispensed may submit an Investigator IND. For more information, see the FDA website on the Investigational New Drug Application Process.

If your study proposal

Proposal
a written offer by an individual or non-federal organization to enter into a contract, consisting of a technical and a business proposal which includes a description of the project and its costs, and the methods, personnel, and facilities to carry it out.

involves an investigational device, you may find more information at FDA Device Advice.

Studies that involve stem cells or human fetal tissue must comply with established federal policies. Stem Cell Information is available from NIH and includes federal policy, guidelines and FAQ's. Human Embryo Research, Cloning and Transplantation describes the policy for NIH funding in this area.

Page Last Updated: February 2011
Content Manager: ClinicalResearchPolicyManager@nhlbi.nih.gov

Skip to content past banner and navigation links U.S. Department of Health & Human Services National Institutes of Health Contact Us Get Email Alerts Font Size Accessible Search Form Advanced Search Search the NHLBI, use radio buttons below to select whole site or Disease and Conditions Index only NHLBI Entire Site NHLBI Entire Site1 Diseases & Conditions2
Home » Clinical Research Guide» Funding» What other approvals are needed?
CRG Home Contracts Overview What is clinical research? What is the role of NIH and NHLBI in clinical research? What are the Project Officer's responsibilities in clinical research? What is the role of the Principal Investigator/Institution in clinical research? Application How can I find funding opportunities (RFAs, RFPs and PAsG)? What do I need to know before submitting a clinical research application? Am I a new investigator and what if this is my first NIH application? Which NHLBI staff can help me? Is my study considered clinical research? Is my study observational or interventional? What is the best award mechanism for my clinical research proposal? What if my project exceeds $500,000 in direct costs in any given year? Where can I get help with writing the application? What must I include in "Protection of Human Subjects"? How and when do I submit my application? Review What happens to my grant after submission? Who will review my application and when? Did the reviewers like my application? What is a summary statement and what does it mean? What if I don't agree with the review? Funding How do I know if I am funded? Who needs human subjects protection training? Who approves my data monitoring plan? What is a Certificate of Confidentiality and do I need one? How do I develop consent forms and who reviews them? Are there ethical concerns and conflicts of interest I must consider? Do I need IRB, IEC or REB approval? What other approvals are needed? How do I track recruitment of research participants? My study involves Medicare or third party support. My study involves foreign grants and contracts. How do I register my study? When can I begin enrolling participants? Management How do I comply with Good Clinical Practices (GCP)? How do I manage changes to my grant? How do I report amendments, suspensions and terminations? Must I obtain continuing review from the IRB? Who should monitor subject recruitment/retention? How do I report adverse events? How is data quality monitored? What if I wish to add extra sites or studies to my project? How do I manage my budget and when are reports expected? What is HIPAA and how do I abide by the requirements ? Study Closure Tools & Training Glossary	What other approvals are needed? Recombinant DNA and Gene Transfer Approval FDA Food and Drug Administration (FDA) is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation. Food and Drug Administration Homepage Drug or Device Studies Approval Stem Cell Study Approval The NIH National Institutes of Health (NIH) the United State's medical research agency, a federal government agency composed of diverse Institutes and Centers that conduct and support biomedical and behavioral research. NIH Homepage. Guidelines for Recombinant DNA state that no research participant will be enrolled in gene transfer studies (Phase I, II, or III) until the Recombinant DNA Advisory Committee ( RAC Recombinant DNA Advisory Committee (RAC) experts whose responsibility it is to review human gene transfer research, receiving NIH funding for recombinant DNA research. Protocols are discussed at quarterly public meetings. RAC Homepage ) review has been completed, Institutional Review Board and Institutional Biosafety Committee ( IBC Institutional Biosafety Committee (IBC) oversight group convened by a research institution under NIH Guidelines for Research Involving Recombinant DNA Molecules to review recombinant DNA research and ensure its legal use. IBCs may also review other biohazardous research, including biodefense select agents. ) approvals have been obtained, and an Investigational New Drug request has been authorized. NIH Guidelines apply to investigators conducting gene transfer research that are supported by NIH or performed at an Institution that receives NIH support for any type of recombinant DNA research. FDA approvals are required for studies that use: An unapproved or unlicensed drug or device. An FDA licensed drug or device used in a manner for which it has not been licensed (“off label use”). A drug or device formulated or developed by an organization that does not hold an FDA license for its manufacture. An unapproved or unlicensed gene delivery vector containing a gene or DNA product. You may need to obtain an IND Investigational New Drug (IND) an application, filed by a drug sponsor with FDA (Form FDA 1571) to conduct clinical trials. It includes detailed descriptions of all trial phases, protocols, IRB members, and investigators or IDE Investigational Device Exemption (IDE) similar to an IND, this allows an unapproved medical device to be used for investigational purposes. approval for your study drug or device. A physician who both initiates and conducts an investigation in which an investigational drug is administered or dispensed may submit an Investigator IND. For more information, see the FDA website on the Investigational New Drug Application Process. If your study proposal Proposal a written offer by an individual or non-federal organization to enter into a contract, consisting of a technical and a business proposal which includes a description of the project and its costs, and the methods, personnel, and facilities to carry it out. involves an investigational device, you may find more information at FDA Device Advice. Studies that involve stem cells or human fetal tissue must comply with established federal policies. Stem Cell Information is available from NIH and includes federal policy, guidelines and FAQ's. Human Embryo Research, Cloning and Transplantation describes the policy for NIH funding in this area. Page Last Updated: February 2011 Content Manager: ClinicalResearchPolicyManager@nhlbi.nih.gov
Twitter Facebook YouTube SEARCH \| ACCESSIBILITY \| READERS & PLAYERS \| SITE INDEX \| OTHER SITES \| PRIVACY STATEMENT \| FOIA \| CONTACT US \| OIG National Institutes of Health Department of Health and Human Services USA.gov

What other approvals are needed?